» Articles » PMID: 24296879

Optimization and Comprehensive Characterization of a Faithful Tissue Culture Model of the Benign and Malignant Human Prostate

Overview
Journal Lab Invest
Specialty Pathology
Date 2013 Dec 4
PMID 24296879
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Few preclinical models accurately depict normal human prostate tissue or primary prostate cancer (PCa). In vitro systems typically lack complex cellular interactions among structured prostatic epithelia and a stromal microenvironment, and genetic and molecular fidelity are concerns in both in vitro and in vivo models. 'Tissue slice cultures' (TSCs) provide realistic preclinical models of diverse tissues and organs, but have not been fully developed or widely utilized for prostate studies. Problems encountered include degeneration of differentiated secretory cells, basal cell hyperplasia, and poor survival of PCa. Here, we optimized, characterized, and applied a TSC model of primary human PCa and benign prostate tissue that overcomes many deficiencies of current in vitro models. Tissue cores from fresh prostatectomy specimens were precision-cut at 300 μm and incubated in a rotary culture apparatus. The ability of varied culture conditions to faithfully maintain benign and cancer cell and tissue structure and function over time was evaluated by immunohistological and biochemical assays. After optimization of the culture system, molecular and cellular responses to androgen ablation and to piperlongumine (PL), purported to specifically reduce androgen signaling in PCa, were investigated. Optimized culture conditions successfully maintained the structural and functional fidelity of both benign and PCa TSCs for 5 days. TSCs exhibited androgen dependence, appropriately undergoing ductal degeneration, reduced proliferation, and decreased prostate-specific antigen expression upon androgen ablation. Further, TSCs revealed cancer-specific reduction of androgen receptor and increased apoptosis upon treatment with PL, validating data from cell lines. We demonstrate a TSC model that authentically recapitulates the structural, cellular, and genetic characteristics of the benign and malignant human prostate, androgen dependence of the native tissue, and cancer-specific response to a potentially new therapeutic for PCa. The work described herein provides a basis for advancing the experimental utility of the TSC model.

Citing Articles

PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways.

Yang J, Wang L, Byrnes J, Kirkemo L, Driks H, Belair C Cancer Immunol Res. 2024; 12(5):575-591.

PMID: 38588410 PMC: 11063765. DOI: 10.1158/2326-6066.CIR-23-0722.


Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations.

Habowski A, Budagavi D, Scherer S, Aurora A, Caligiuri G, Flynn W Cancers (Basel). 2024; 16(3).

PMID: 38339316 PMC: 10854945. DOI: 10.3390/cancers16030565.


New uses for an old technique: live imaging on the slice organ culture to study reproductive processes†.

Amato C, Hung-Chang Yao H Biol Reprod. 2024; 110(6):1055-1064.

PMID: 38315794 PMC: 11180704. DOI: 10.1093/biolre/ioae023.


The Antitumor Activity of Piplartine: A Review.

Duarte A, Gomes R, Nunes V, Goncalves J, Correia C, Dos Santos A Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765054 PMC: 10535094. DOI: 10.3390/ph16091246.


Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth.

Zhou Z, Jia D, Kwon O, Li S, Sun H, Roudier M Oncogene. 2023; 42(32):2428-2438.

PMID: 37400528 PMC: 10802183. DOI: 10.1038/s41388-023-02759-7.


References
1.
Sonpavde G, Palapattu G . Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials. Expert Rev Anticancer Ther. 2010; 10(3):439-50. DOI: 10.1586/era.10.17. View

2.
Rambani K, Vukasinovic J, Glezer A, Potter S . Culturing thick brain slices: an interstitial 3D microperfusion system for enhanced viability. J Neurosci Methods. 2009; 180(2):243-54. PMC: 2742628. DOI: 10.1016/j.jneumeth.2009.03.016. View

3.
Behrsing H, Vickers A, Tyson C . Extended rat liver slice survival and stability monitored using clinical biomarkers. Biochem Biophys Res Commun. 2003; 312(1):209-13. DOI: 10.1016/j.bbrc.2003.09.216. View

4.
Dabir P, Ottosen P, Hoyer S, Hamilton-Dutoit S . Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma. Diagn Pathol. 2012; 7:81. PMC: 3434074. DOI: 10.1186/1746-1596-7-81. View

5.
Taylor R, Risbridger G . Prostatic tumor stroma: a key player in cancer progression. Curr Cancer Drug Targets. 2008; 8(6):490-7. DOI: 10.2174/156800908785699351. View